Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (1934)	3/23/2002 8:39:12 PM
From: scaram(o)uche	Respond to of 10345

Thanks. Yes, scientific meetings are a real pain. Focusing on a given element of that program....... mcnd.org (for those unfamiliar with the story, Merck is hoping that a substance P antagonist will sell at north of $5 billion/year..... so, it's worth the time and effort to follow up on Bill's thought. Elan also lists a project with Merck in phase II, and the substance P antagonist is in phase II for depression.) No focus to this post, so I'll continue.... follow the bouncing ball........ Message 17238034